STAG2 and cancer: Of note, cohesin (STAG2)-mutated cancers have been reported to display strong activation of IFN and NF-kB expression signatures, along with PD-L1 upregulation [118], thus providing another rationale for adding anti-PD(L)1 immunotherapy in STAG2-mutated AML.